Teleflex (NYSE:TFX) Cut to Strong Sell at Zacks Research

Zacks Research cut shares of Teleflex (NYSE:TFX) from a hold rating to a strong sell rating in a research report report published on Monday,Zacks.com reports.

Several other equities analysts also recently issued reports on the stock. Royal Bank Of Canada lifted their price target on shares of Teleflex from $115.00 to $125.00 and gave the company a “sector perform” rating in a report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Teleflex in a report on Monday, December 29th. Wall Street Zen downgraded Teleflex from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Truist Financial increased their price target on Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a research report on Thursday, December 18th. Finally, Needham & Company LLC raised their price target on Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Teleflex has a consensus rating of “Hold” and a consensus price target of $140.83.

Teleflex Price Performance

Shares of TFX stock opened at $119.46 on Monday. The stock’s fifty day simple moving average is $111.25 and its 200 day simple moving average is $118.70. Teleflex has a one year low of $100.18 and a one year high of $143.32. The firm has a market cap of $5.28 billion, a price-to-earnings ratio of -5.81, a P/E/G ratio of 0.78 and a beta of 0.87. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.54 and a quick ratio of 2.01.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.73 by ($1.80). Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.The company had revenue of $569.00 million for the quarter, compared to analyst estimates of $912.57 million. During the same quarter in the prior year, the company earned $3.89 earnings per share. The business’s revenue was down 28.5% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, analysts expect that Teleflex will post 13.98 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Friday, March 6th will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Friday, March 6th. Teleflex’s dividend payout ratio (DPR) is presently -6.62%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of TFX. Janus Henderson Group PLC raised its stake in shares of Teleflex by 2.0% during the fourth quarter. Janus Henderson Group PLC now owns 4,246,112 shares of the medical technology company’s stock worth $518,196,000 after buying an additional 84,754 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Teleflex by 478.1% during the 3rd quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock valued at $287,603,000 after acquiring an additional 1,956,811 shares during the last quarter. State Street Corp lifted its stake in shares of Teleflex by 1.5% in the 4th quarter. State Street Corp now owns 1,478,776 shares of the medical technology company’s stock valued at $180,470,000 after purchasing an additional 22,111 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Teleflex by 0.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,250,665 shares of the medical technology company’s stock worth $152,630,000 after purchasing an additional 5,051 shares during the last quarter. Finally, Cooke & Bieler LP grew its stake in shares of Teleflex by 1.2% during the third quarter. Cooke & Bieler LP now owns 1,220,637 shares of the medical technology company’s stock worth $149,357,000 after purchasing an additional 14,673 shares during the period. Institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.